

## Accepted Manuscript

Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes

Eric P. Hoffman, Valerie Riddle, Maxime A. Siegler, Daniel Dickerson, Miroslav Backonja, William G. Kramer, Kanneboyina Nagaraju, Heather Gordish-Dressman, Jesse M. Damsker, John M. McCall

PII: S0039-128X(18)30045-X  
DOI: <https://doi.org/10.1016/j.steroids.2018.02.010>  
Reference: STE 8237

To appear in: *Steroids*

Received Date: 28 January 2018  
Revised Date: 22 February 2018  
Accepted Date: 26 February 2018

Please cite this article as: Hoffman, E.P., Riddle, V., Siegler, M.A., Dickerson, D., Backonja, M., Kramer, W.G., Nagaraju, K., Gordish-Dressman, H., Damsker, J.M., McCall, J.M., Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes, *Steroids* (2018), doi: <https://doi.org/10.1016/j.steroids.2018.02.010>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes

### Authors:

Eric P. Hoffman, PhD<sup>1,2\*</sup>; Valerie Riddle, MD<sup>3</sup>; Maxime A. Siegler, PhD<sup>4</sup>; Daniel Dickerson, MD<sup>5</sup>; Miroslav Backonja, MD<sup>6</sup>; William G. Kramer, PhD<sup>6</sup>; Kanneboyina Nagaraju, DVM PhD<sup>1,2</sup>; Heather Gordish-Dressman, PhD<sup>7</sup>; Jesse M. Damsker, PhD<sup>1</sup>; John M. McCall, PhD<sup>1</sup>

### Affiliations:

<sup>1</sup> ReveraGen BioPharma, Rockville, MD USA

<sup>2</sup> Department of Pharmaceutical Sciences, School of Pharmacy, Binghamton University – SUNY, Binghamton, NY USA

<sup>3</sup> BioPharmAdvisors LLC USA.

<sup>4</sup> Department of Chemistry, Johns Hopkins University, 3400 N. Charles St., Baltimore, MD, 21218

<sup>5</sup> PRA Health Sciences, Lenexa, KS USA

<sup>6</sup> Kramer Consulting LLC, USA

<sup>7</sup> Children's National Medical Center, Washington DC USA

\*To whom correspondence should be addressed: ericphoffman@gmail.com

**Running Title:** Phase 1 clinical trial of vamorolone.

**One Sentence Summary:** Vamorolone is shown to be a dissociative steroid, with a crystal structure consistent with binding to the glucocorticoid and mineralocorticoid receptors, but loss of dimerization and associated side effects.

**Author Contributions:** Eric P. Hoffman (design, conduct, oversight, Sponsor, writing); Valerie Riddle (Medical Monitor); Maxine A. Siegler (X-ray crystallography); Daniel Dickerson (Study Director); Miroslav Backonja (Study Director); William G. Kramer (pharmacokinetics, data interpretation); Kanneboyina Nagaraju (biomarker studies); Heather Gordish-Dressman (statistics); Jesse M. Damsker (project management, data interpretation, biomarkers); John M. McCall (medicinal chemistry, X-ray crystallography, manuscript writing)

Download English Version:

<https://daneshyari.com/en/article/8366227>

Download Persian Version:

<https://daneshyari.com/article/8366227>

[Daneshyari.com](https://daneshyari.com)